Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "Lupin"

315 News Found

Lupin receives USFDA approval for topical solution
Drug Approval | March 03, 2022

Lupin receives USFDA approval for topical solution

The product will be manufactured at Lupin’s facility in Pithampur, India


Lupin launches Sevelamer Hydrochloride tablets in the United States
Drug Approval | March 01, 2022

Lupin launches Sevelamer Hydrochloride tablets in the United States

Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg


Dr Fabrice Egros gets an additional role at Lupin
People | February 23, 2022

Dr Fabrice Egros gets an additional role at Lupin

He will continue to lead business in LATAM and Asia regions in this new role


USFDA approves Lupin’s Supplemental New Drug Application for Solosec
Drug Approval | February 17, 2022

USFDA approves Lupin’s Supplemental New Drug Application for Solosec

The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV


Lupin signs distribution agreement with Medis for Orphan Drug NaMuscla@
News | February 09, 2022

Lupin signs distribution agreement with Medis for Orphan Drug NaMuscla@

NDM disorders are a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction


Lupin receives approval from USFDA for Arformoterol Tartrate inhalation
Drug Approval | February 08, 2022

Lupin receives approval from USFDA for Arformoterol Tartrate inhalation

Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)


Lupin Q3FY22 PAT at Rs 545.52 cr.
News | February 04, 2022

Lupin Q3FY22 PAT at Rs 545.52 cr.

Lupin has reported consolidated financial results for the period ended December 31, 2021


Lupin signs deal with Axantia to market pegfilgrastim in Middle East and Africa
News | February 01, 2022

Lupin signs deal with Axantia to market pegfilgrastim in Middle East and Africa

Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy


Lupin signs promotional agreement with Exeltis on SOLOSEC
News | January 28, 2022

Lupin signs promotional agreement with Exeltis on SOLOSEC

SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment


Lupin ties up with Foncoo of China
News | January 19, 2022

Lupin ties up with Foncoo of China

This is the company’s first partnership arrangement in China